EcoDrugPlus

Carbonic Anhydrase Iv C

Ensembl ID : ENSLCAG00010021202
Gene Symbol: CA4C
1 Cross references
79 Possible Orthologues:

Carbonic Anhydrase Vii

Ensembl ID : ENSLCAG00010005006
Gene Symbol: LOC108887651
4 Cross references
221 Possible Orthologues:

Carbonic Anhydrase Va

Ensembl ID : ENSLCAG00010017284
Gene Symbol: CA5A
4 Cross references
231 Possible Orthologues:

Carbonic Anhydrase Xiv

Ensembl ID : ENSLCAG00010024866
Gene Symbol: LOC108885915
4 Cross references
210 Possible Orthologues:

Casein Kinase 1 Epsilon

Ensembl ID : ENSLCAG00010012154
Gene Symbol: CSNK1E
4 Cross references
211 Possible Orthologues:

Casein Kinase 1, Epsilon

Ensembl ID : ENSLCAG00010000432
Gene Symbol: CSNK1E
2 Cross references
196 Possible Orthologues:

Caspase 9, Apoptosis-Related Cysteine Peptidase

Ensembl ID : ENSLCAG00010027848
Gene Symbol: LOC108882570
4 Cross references
202 Possible Orthologues:

Catechol-O-Methyltransferase B

Ensembl ID : ENSLCAG00010018721
Gene Symbol: COMTB
1 Cross references
215 Possible Orthologues:

Cathepsin C

Ensembl ID : ENSLCAG00010021706
Gene Symbol: LOC108886624
4 Cross references
237 Possible Orthologues:

Cathepsin K

Ensembl ID : ENSLCAG00010004516
Gene Symbol: LOC108883173
4 Cross references
219 Possible Orthologues:

Cathepsin S, Ortholog2, Tandem Duplicate 1

Ensembl ID : ENSLCAG00010004540
Gene Symbol: CTSS2.1
4 Cross references
233 Possible Orthologues:

Cell Division Cycle 7 Homolog (S. Cerevisiae)

Ensembl ID : ENSLCAG00010022772
Gene Symbol: LOC108883712
4 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).